Literature DB >> 24129666

Hemoglobin stability and patient satisfaction after switch to C.E.R.A. therapy: a multicenter, observational study.

Fuat Bozkurt1, Heribert-Ewald Fink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24129666     DOI： 10.1007/s40261-013-0142-5

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  8 in total

1.  Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study.

Authors:  D Fliser; W Kleophas; F Dellanna; F Dellana; R E Winkler; W Backs; U Kraatz; W Fassbinder; V Wizemann; G Strack
Journal:  Curr Med Res Opin       Date:  2010-05       Impact factor: 2.580

2.  Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.

Authors:  Stefan Heidenreich; Frank Leistikow; Stefan Zinn; Jörg Baumann; Andreas Atzeni; Vitomir Bajeski; Jörn Dietzmann; Gert-Peter Dragoun
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

3.  Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.

Authors:  Thomas Weinreich; Frank Leistikow; Hagen-Georg Hartmann; Günter Vollgraf; Frank Dellanna
Journal:  Hemodial Int       Date:  2012-01       Impact factor: 1.812

4.  Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

Authors:  Nathan W Levin; Steven Fishbane; Francisco Valdés Cañedo; Steven Zeig; George M Nassar; John E Moran; Giuseppe Villa; Ulrich Beyer; Delphine Oguey
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

5.  Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.

Authors:  Fernando Carrera; Charmaine E Lok; Angel de Francisco; Francesco Locatelli; Johannes F E Mann; Bernard Canaud; Peter G Kerr; Iain C Macdougall; Anatole Besarab; Giuseppe Villa; Isabelle Kazes; Bruno Van Vlem; Shivinder Jolly; Ulrich Beyer; Frank C Dougherty
Journal:  Nephrol Dial Transplant       Date:  2010-06-03       Impact factor: 5.992

6.  Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

Authors:  Francesco Locatelli; Giuseppe Villa; Angel L M de Francisco; Alberto Albertazzi; Horacio J Adrogue; Frank C Dougherty; Ulrich Beyer
Journal:  Curr Med Res Opin       Date:  2007-05       Impact factor: 2.580

7.  Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Authors:  Wladyslaw Sulowicz; Francesco Locatelli; Jean-Philippe Ryckelynck; Jozsef Balla; Botond Csiky; Kevin Harris; Patricia Ehrhard; Ulrich Beyer
Journal:  Clin J Am Soc Nephrol       Date:  2007-05-23       Impact factor: 8.237

8.  C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

Authors:  Simon D Roger; Francesco Locatelli; Rainer P Woitas; Maurice Laville; Sheldon W Tobe; Robert Provenzano; Thomas A Golper; Prajej Ruangkanchanasetr; Ho Yung Lee; Kwan-Dun Wu; Michal Nowicki; Agnes Ladanyi; Alberto Martínez-Castelao; Ulrich Beyer; Frank C Dougherty
Journal:  Nephrol Dial Transplant       Date:  2011-04-19       Impact factor: 5.992
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.